Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,334.00

Eli Lilly and Company (NYSE:LLY) had its target price raised by equities researchers at Bank of America from $1,251.00 to $1,334.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 12.67% from the stock’s current price.

A number of other research firms have also recently commented on LLY. Morgan Stanley increased their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research note on Wednesday. Wolfe Research reiterated an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a report on Monday. Berenberg Bank boosted their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research report on Monday, June 22nd. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,263.41.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $32.97 during trading hours on Friday, hitting $1,183.98. The stock had a trading volume of 1,168,878 shares, compared to its average volume of 3,199,250. The company has a 50 day simple moving average of $1,091.91 and a two-hundred day simple moving average of $1,032.43. The firm has a market capitalization of $1.11 trillion, a price-to-earnings ratio of 42.07, a P/E/G ratio of 1.51 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.During the same quarter last year, the business posted $3.34 earnings per share. The firm’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts forecast that Eli Lilly and Company will post 35.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of LLY. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $25,000. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC increased its position in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares in the last quarter. Basso Capital Management L.P. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $30,000. Finally, Maseco LLP lifted its holdings in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares during the period. Institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly said its Phase 2 neuropathic pain trial reached completion, giving investors another readout to watch for in a potentially large new market. Eli Lilly’s New Neuropathic Pain Trial Reaches Phase 2 Completion: What Investors Should Watch
• Positive Sentiment: Several articles highlighted surging demand for Lilly’s GLP-1 drugs, with sales still accelerating and reinforcing the company’s dominant position in obesity and diabetes treatments. Record Numbers of Americans Are on GLP-1 Drugs. That’s Great News for This Stock.
• Positive Sentiment: Wall Street sentiment remains upbeat, with JPMorgan and RBC reportedly raising price targets, while analysts continue to view Lilly as a strong growth story. JPMorgan resets LLY stock target on drug demand
• Positive Sentiment: Reports that top funds were buying Lilly shares suggest institutional investors are still adding exposure to the name. Top Funds Bet Big On 19 Stocks — Including Eye-Popping Sums On These Five
• Neutral Sentiment: Lilly also announced upcoming Alzheimer’s research presentations at AAIC 2026, which adds to its long-term pipeline narrative but is not an immediate commercial catalyst. Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026
• Negative Sentiment: Tampa General Hospital sued Lilly over alleged pulled 340B discounts, creating a legal and reputational risk around pricing and access practices. Tampa General sues Eli Lilly for allegedly pulling 340B discounts

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.